PERUSE. A multicenter, single-arm study of pertuzumab in combination with CLOSED - trastuzumab and a taxane in first 12/LO/0482 4 30/11/2013 In NO treatment of patients with HER2-positive advanced (metastatic or locally recurrent) breast cancer. FOCUS FH. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety and Efficacy of Two Different CLOSED - 12/NW/0014 Regimens of Mipomersen in 6 22/11/2013 In NO Patients with Familial Hypercholesterolemia and Inadequately Controlled (MIP038) ALLOS PDX-017. A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with CLOSED - Previously Undiagnosed 10/H0718/93 7 30/08/2013 In NO Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy ALTERNATIVE. Comparing safety & efficacy of 11/LO/1619 5 02/01/2015 CLOSED NO AI/lapatanib/trastuzumab in HR+HER2 MBC
12/LO/0482 PERUSE. A multicenter, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first treatment of patients with HER2-positive advanced (metastatic or locally recurrent) breast cancer. 4 30/11/2013 CLOSED - In NO 12/NW/0014 FOCUS FH. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled (MIP038) 6 22/11/2013 CLOSED - In NO 10/H0718/93 ALLOS PDX-017. A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy 7 30/08/2013 CLOSED - In NO 11/LO/1619 ALTERNATIVE. Comparing safety & efficacy of AI/lapatanib/trastuzumab in HR+HER2 MBC 5 02/01/2015 CLOSED NO
PID-Q22016-17.docx